UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2019-05, Vol.30 (5), p.706-720

2019

Volltextzugriff (PDF)

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2016-09, Vol.27 (suppl 5), p.v58-v68

2016

Volltextzugriff (PDF)

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

Annals of oncology, 2021-12, Vol.32 (12), p.1511-1519

2021

Volltextzugriff (PDF)

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2014-09, Vol.25 Suppl 3, p.iii49-iii56

2014

Volltextzugriff (PDF)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Volltextzugriff (PDF)

Clinical biomarkers of response in advanced renal cell carcinoma

Annals of oncology, 2013-12, Vol.24 (12), p.2935-2942

2013

Volltextzugriff (PDF)

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2024-08, Vol.35 (8), p.692-706

2024

Volltextzugriff (PDF)

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

ESMO open, 2021-02, Vol.6 (1), p.100030, Article 100030

2021

Volltextzugriff (PDF)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

ESMO open, 2023-06, Vol.8 (3), p.101210-101210, Article 101210

2023

Volltextzugriff (PDF)

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Annals of oncology, 2018-10, Vol.29, p.viii724-viii724

2018

Volltextzugriff (PDF)

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO open, 2021-02, Vol.6 (1), p.100035-100035

2021

Volltextzugriff (PDF)

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

British journal of cancer, 2006-09, Vol.95 (6), p.691-698

2006

Volltextzugriff (PDF)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

ESMO open, 2022-04, Vol.7 (2), p.100450-100450, Article 100450

2022

Volltextzugriff (PDF)

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

ESMO open, 2021-08, Vol.6 (4), p.100122-100122, Article 100122

2021

Volltextzugriff (PDF)

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

Annals of oncology, 2018-10, Vol.29, p.viii313-viii313

2018

Volltextzugriff (PDF)

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

ESMO open, 2023-12, Vol.8 (6), p.102034-102034, Article 102034

2023

Volltextzugriff (PDF)

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

ESMO open, 2021-04, Vol.6 (2), p.100057-100057, Article 100057

2021

Volltextzugriff (PDF)

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

Annals of oncology, 2002-05, Vol.13 (5), p.653-668

2002

Volltextzugriff (PDF)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

ESMO open, 2021-12, Vol.6 (6), p.100304-100304, Article 100304

2021

Volltextzugriff (PDF)

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

European urology open science (Online), 2022-08, Vol.42, p.S10

2022

Volltextzugriff (PDF)

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

World journal of urology, 2017-04, Vol.35 (4), p.641-648

2017

Volltextzugriff (PDF)

MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S135-S135

2016

Volltextzugriff (PDF)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Volltextzugriff (PDF)

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

European journal of cancer (1990), 2017-02, Vol.72, p.S187-S188

2017

Volltextzugriff (PDF)

CD98hc (SLC3A2), a novel marker in renal cell cancer

European journal of clinical investigation, 2009-04, Vol.39 (4), p.304-310

2009

Volltextzugriff (PDF)

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(250)
Mit Volltextzugriff
(245)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(127)
Humans
(121)
Female
(81)
Male
(76)
Middle Aged
(67)
Aged
(54)
Oncology
(53)
Biological And Medical Sciences
(50)
Medical Sciences
(48)
Adult
(43)
Treatment Outcome
(29)
Carcinoma, Renal Cell - Drug Therapy
(27)
Kidney Neoplasms - Drug Therapy
(26)
Renal Cell Carcinoma
(26)
Cardiac & Cardiovascular Systems
(23)
Cardiovascular System & Cardiology
(23)
Aged, 80 And Over
(20)
Follow-Up Studies
(20)
Kidney Neoplasms - Pathology
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Clinical biomarkers of response in advanced renal cell carcinoma

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL study)

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms

MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

CD98hc (SLC3A2), a novel marker in renal cell cancer

Suchergebnisse filtern